David MacPherson

Summary

Affiliation: Carnegie Institution
Country: USA

Publications

  1. ncbi Retinoblastoma: from the two-hit hypothesis to targeted chemotherapy
    David MacPherson
    Department of Embryology, Carnegie Institution, Baltimore, Maryland, USA
    Cancer Res 67:7547-50. 2007
  2. ncbi Insights from mouse models into human retinoblastoma
    David MacPherson
    Department of Embryology, Carnegie Institution, Baltimore, MD, USA
    Cell Div 3:9. 2008
  3. ncbi Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification
    David MacPherson
    Department of Embryology, Carnegie Institution, Baltimore, MD 21218, USA
    EMBO J 26:784-94. 2007
  4. ncbi Cooperation between Rb and Arf in suppressing mouse retinoblastoma
    Karina Conkrite
    Department of Embryology, Carnegie Institution, Baltimore, Maryland 21218, USA
    J Clin Invest 122:1726-33. 2012
  5. ncbi miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma
    Karina Conkrite
    Department of Embryology, Carnegie Institution, Baltimore, Maryland 21218, USA
    Genes Dev 25:1734-45. 2011
  6. ncbi Cell type-specific effects of Rb deletion in the murine retina
    David MacPherson
    Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Genes Dev 18:1681-94. 2004
  7. ncbi Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23
    David MacPherson
    MIT Department of Biology and Center for Cancer Research, Cambridge, MA, USA
    EMBO J 23:3689-99. 2004
  8. ncbi BACE-1 inhibitors part 3: identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells
    Paul Beswick
    Neurology and Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline R and D, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, UK
    Bioorg Med Chem Lett 18:1022-6. 2008
  9. ncbi ARF mutation accelerates pituitary tumor development in Rb+/- mice
    Kenneth Y Tsai
    Department of Biology and Center for Cancer Research, and Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 99:16865-70. 2002
  10. ncbi ARF is not required for apoptosis in Rb mutant mouse embryos
    Kenneth Y Tsai
    MIT Department of Biology and Center for Cancer Research, Cambridge, MA 02139, USA
    Curr Biol 12:159-63. 2002

Research Grants

  1. Using mouse models to understand retinoblastoma initiation and progression
    David MacPherson; Fiscal Year: 2010

Collaborators

  • Michael Dyer
  • Karina Conkrite
  • Kenneth Y Tsai
  • David Mu
  • Maggie Sundby
  • Shizuo Mukai
  • Paul Beswick
  • Douglas A Rubinson
  • Tyler Jacks
  • Denise Crowley
  • J Michael Thomson
  • Scott M Hammond
  • Emmanuel Demont
  • Gareth Wayne
  • Alistair Stuart
  • Sharon Sweitzer
  • John Skidmore
  • Pam Theobald
  • Alistair O'Brien
  • Paul Rowland
  • Peter Milner
  • Rachel Dunsdon
  • Nicolas Charrier
  • Ishrut Hussain
  • Virginie Soleil
  • Sally Redshaw
  • David Vesey
  • John Ward
  • Julie Hawkins
  • Alan Naylor
  • Brian Clarke
  • Julie Mosley
  • Graham Maile
  • Kathrine J Smith
  • Rosalie Matico
  • Daryl S Walter
  • David Riddell
  • Steven Stanway
  • Christopher N Johnson
  • Geoffrey Stemp
  • Andrew Faller
  • Robert Gleave
  • Colin Dingwall
  • Alexander Yu Nikitin
  • Kim L Mercer
  • Roderick Bronson

Detail Information

Publications10

  1. ncbi Retinoblastoma: from the two-hit hypothesis to targeted chemotherapy
    David MacPherson
    Department of Embryology, Carnegie Institution, Baltimore, Maryland, USA
    Cancer Res 67:7547-50. 2007
    ..More importantly, these new mouse models of retinoblastoma have contributed to clinical trials and novel therapeutic approaches for treating this debilitating childhood cancer...
  2. ncbi Insights from mouse models into human retinoblastoma
    David MacPherson
    Department of Embryology, Carnegie Institution, Baltimore, MD, USA
    Cell Div 3:9. 2008
    ..Recent investigation of the p53 pathway in retinoblastoma, and evidence of spatial topology to early murine retinoblastoma are also discussed in this review...
  3. ncbi Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification
    David MacPherson
    Department of Embryology, Carnegie Institution, Baltimore, MD 21218, USA
    EMBO J 26:784-94. 2007
    ..These murine models closely resemble human retinoblastoma in their progression and secondary genetic changes, making them ideal tools for further dissection of steps to tumorigenesis and for testing novel therapies...
  4. ncbi Cooperation between Rb and Arf in suppressing mouse retinoblastoma
    Karina Conkrite
    Department of Embryology, Carnegie Institution, Baltimore, Maryland 21218, USA
    J Clin Invest 122:1726-33. 2012
    ..Moreover, p53 inactivation completely eliminated any selection for Arf LOH. Thus, our data reveal important insights into the p53 pathway in retinoblastoma and show that Arf is a key collaborator with Rb in retinoblastoma suppression...
  5. ncbi miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma
    Karina Conkrite
    Department of Embryology, Carnegie Institution, Baltimore, Maryland 21218, USA
    Genes Dev 25:1734-45. 2011
    ..These results demonstrate that the oncogenic determinants of miR-17~92 are context-specific and provide new insights into miR-17~92 function as an RB-collaborating gene in cancer...
  6. ncbi Cell type-specific effects of Rb deletion in the murine retina
    David MacPherson
    Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Genes Dev 18:1681-94. 2004
    ..Conditional Rb mutation in the retina did not result in retinoblastoma formation even in a p53-mutant background. However, on a p107- or p130-deficient background, Rb mutation in the retina caused retinal dysplasia or retinoblastoma...
  7. ncbi Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23
    David MacPherson
    MIT Department of Biology and Center for Cancer Research, Cambridge, MA, USA
    EMBO J 23:3689-99. 2004
    ..Instead, Ser23 mutant animals died between 1 and 2 years with tumors that were most commonly of B-cell lineage. These data support an important role for Ser20/23 phosphorylation in p53 stabilization, apoptosis and tumor suppression...
  8. ncbi BACE-1 inhibitors part 3: identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells
    Paul Beswick
    Neurology and Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline R and D, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, UK
    Bioorg Med Chem Lett 18:1022-6. 2008
    ..Optimization of the non-prime side of our inhibitors and introduction of a 6-membered sultam substituent binding to Asn-294 as well as a fluorine in the C-2 position led to derivatives with nanomolar potency in cell-based assays...
  9. ncbi ARF mutation accelerates pituitary tumor development in Rb+/- mice
    Kenneth Y Tsai
    Department of Biology and Center for Cancer Research, and Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 99:16865-70. 2002
    ..We conclude that inactivation of ARF acts more broadly than that of p53 in connecting abrogation of the Rb pathway to tumorigenesis...
  10. ncbi ARF is not required for apoptosis in Rb mutant mouse embryos
    Kenneth Y Tsai
    MIT Department of Biology and Center for Cancer Research, Cambridge, MA 02139, USA
    Curr Biol 12:159-63. 2002
    ..From the analysis of Rb/ARF compound mutants we demonstrate that ARF is not an obligatory link between Rb inactivation and p53-dependent apoptosis...

Research Grants1

  1. Using mouse models to understand retinoblastoma initiation and progression
    David MacPherson; Fiscal Year: 2010
    ..We use mouse models and studies of human retinoblastoma samples to learn how RB- cooperating genes contribute to cancer. ..